CD8 T-Cell–Predominant Lymphocytic Esophagitis Associated with GERD
|
By LabMedica International staff writers Posted on 05 Oct 2021 |

Image: Histopathology photomicrograph of lymphocytic esophagitis: Esophageal mucosa showing peripapillary intraepithelial lymphocytosis with basal zone hyperplasia and intercellular edema. No significant population of eosinophils or neutrophils is identified (Photo courtesy of Yusuf Kasirye, MD, et al)
In patients with reflux esophagitis (RE), increased lymphocytes are often part of a mixed inflammatory infiltrate that also includes eosinophils and/or neutrophils. Less frequently, lymphocytes are the only type of inflammatory cells associated with gastroesophageal reflux disease (GERD).
One such pattern is lymphocytic esophagitis (LyE), which is characterized by an elevated number of peripapillary lymphocytes and absent or rare intraepithelial granulocytes. This pattern has been reported in approximately 5% of patients with endoscopic esophagitis and 7% of patients with Barrett esophagus.
Clinical Scientists at the Dartmouth-Hitchcock Medical Center (Lebanon, NH, USA) conducted an observational retrospective study and identified 161 patients seen at their institution from 1998 to 2014 who were diagnosed with GERD, had normal esophageal motility, and available esophageal biopsies. For all patients meeting inclusion criteria, the team obtained demographic data as well as information pertaining to clinical diagnosis, past medical history, and endoscopic, imaging, manometry, and, where available, pH-metry findings from the files and electronic medical records.
Biopsy specimens were fixed in 10% formalin, paraffin-embedded, and stained with hematoxylin-eosin. A single peripapillary lymphoid infiltrate was sufficient for the diagnosis of LyE. The cutoffs for a normal number of intraepithelial lymphocytes evaluated in hematoxylin-eosin–stained slides at different levels, such as gastroesophageal junction, distal esophagus, and midesophagus were 62, 46, and 41 lymphocytes per high-power field, respectively. Cells were counted in one mostly affected high-power field using an Olympus BX 41 microscope (Olympus, Center Valley, PA, USA). Routine CD4 and CD8 immunohistochemistry was performed using Bond Polymer Refine Detection staining reagents and Bond III autostainer (Leica Microsystems, Buffalo Grove, IL, USA).
The scientists found increased intraepithelial lymphocytes in 13.7% of patients with GERD. Two major patterns and one minor pattern of lymphocytic inflammation were observed as follows: (1) LyE (in 6.8% [11 of 161] of patients and typically focal), (2) dispersed lymphocytes in an area of reflux esophagitis (in 5.6% [9 of 161] and typically diffuse), and (3) peripapillary lymphocytes in an area of reflux esophagitis (in 1.2% [2 of 161]). CD8 T cells significantly outnumbered CD4 T cells in 91% of patients with lymphocytic esophagitis and 100% of patients with dispersed lymphocytes (9 of 9) or peripapillary lymphocytes (2 of 2) in the area of reflux esophagitis.
The authors concluded that their findings suggest that LyE is one of the major patterns of lymphocytic inflammation in GERD. CD8 T-cell–predominant immunophenotype may be useful as a marker of GERD in the differential diagnosis of LyE. The study was published in the September 2021 issue of the journal Archives of Pathology and Laboratory Medicine.
Related Links:
Dartmouth-Hitchcock Medical Center
Olympus
Leica Microsystems
One such pattern is lymphocytic esophagitis (LyE), which is characterized by an elevated number of peripapillary lymphocytes and absent or rare intraepithelial granulocytes. This pattern has been reported in approximately 5% of patients with endoscopic esophagitis and 7% of patients with Barrett esophagus.
Clinical Scientists at the Dartmouth-Hitchcock Medical Center (Lebanon, NH, USA) conducted an observational retrospective study and identified 161 patients seen at their institution from 1998 to 2014 who were diagnosed with GERD, had normal esophageal motility, and available esophageal biopsies. For all patients meeting inclusion criteria, the team obtained demographic data as well as information pertaining to clinical diagnosis, past medical history, and endoscopic, imaging, manometry, and, where available, pH-metry findings from the files and electronic medical records.
Biopsy specimens were fixed in 10% formalin, paraffin-embedded, and stained with hematoxylin-eosin. A single peripapillary lymphoid infiltrate was sufficient for the diagnosis of LyE. The cutoffs for a normal number of intraepithelial lymphocytes evaluated in hematoxylin-eosin–stained slides at different levels, such as gastroesophageal junction, distal esophagus, and midesophagus were 62, 46, and 41 lymphocytes per high-power field, respectively. Cells were counted in one mostly affected high-power field using an Olympus BX 41 microscope (Olympus, Center Valley, PA, USA). Routine CD4 and CD8 immunohistochemistry was performed using Bond Polymer Refine Detection staining reagents and Bond III autostainer (Leica Microsystems, Buffalo Grove, IL, USA).
The scientists found increased intraepithelial lymphocytes in 13.7% of patients with GERD. Two major patterns and one minor pattern of lymphocytic inflammation were observed as follows: (1) LyE (in 6.8% [11 of 161] of patients and typically focal), (2) dispersed lymphocytes in an area of reflux esophagitis (in 5.6% [9 of 161] and typically diffuse), and (3) peripapillary lymphocytes in an area of reflux esophagitis (in 1.2% [2 of 161]). CD8 T cells significantly outnumbered CD4 T cells in 91% of patients with lymphocytic esophagitis and 100% of patients with dispersed lymphocytes (9 of 9) or peripapillary lymphocytes (2 of 2) in the area of reflux esophagitis.
The authors concluded that their findings suggest that LyE is one of the major patterns of lymphocytic inflammation in GERD. CD8 T-cell–predominant immunophenotype may be useful as a marker of GERD in the differential diagnosis of LyE. The study was published in the September 2021 issue of the journal Archives of Pathology and Laboratory Medicine.
Related Links:
Dartmouth-Hitchcock Medical Center
Olympus
Leica Microsystems
Latest Pathology News
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Channels
Clinical Chemistry
view channel
Blood Test Improves Alzheimer’s Diagnosis and Management Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read moreMolecular Diagnostics
view channel
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Many adults inherit genetic changes that increase their risk for cancer and cardiovascular disease, yet access to testing often remains concentrated in large medical centers. Reaching rural and socially... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more








